TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20730056

Group type: EXPERIMENTAL
Intervention: Milk fortified with 2.4 g/day of prebiotic oligosaccharide and 1.9x10(7) c.f.u/day of probiotic Bifidobacterium lactis HN019
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Milk fortified with prebiotic and probiotic
Number of subjects: 624

Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 624
Study: 19123877

Group type: EXPERIMENTAL
Intervention: Massage-myofascial induction
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo (sham ultrasound/magnetotherapy)
Number of subjects: 62
Study: 16838539

Group type: EXPERIMENTAL
Intervention: Random-frequency two-tone complex
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Fixed-frequency two-tone complex
Number of subjects: 2

Group type: COMPARATOR
Intervention: Broadband noise
Number of subjects: 2
Study: 12871456

Group type: EXPERIMENTAL
Intervention: Graduated elastic compression stockings (ECS) worn during treadmill exercise sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No graduated elastic compression stockings (no ECS) during treadmill exercise sessions
Number of subjects: 0
Study: 10823430

Group type: EXPERIMENTAL
Intervention: Fixation with a CSLP plate
Number of subjects: 46

Group type: COMPARATOR
Intervention: No internal fixation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (plate and no plate)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Patients with excellent or good results according to Odom's criteria
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Test-retest procedure
Number of subjects: 46
Study: 8895943

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Overall patient cohort
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 21
Study: 8341503

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 26

Group type: COMPARATOR
Intervention: No intraocular lens (IOL) implantation
Number of subjects: 26
Study: 3786334

Group type: EXPERIMENTAL
Intervention: 2 mg nasal nicotine solution (NNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.15 mg nasal nicotine solution (NNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2.5 mg mecamylamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated dosing with 2 mg NNS hourly for six hours
Number of subjects: 0
Study: 29139314

Group type: EXPERIMENTAL
Intervention: Recombinant factor VIIIFc (rFVIIIFc)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled comparator (recombinant factor VIII products)
Number of subjects: 0
Study: 27421287

Group type: EXPERIMENTAL
Intervention: Building Wealth and Health Network intervention (28-week duration)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Partial and full intervention groups
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 24249780

Group type: EXPERIMENTAL
Intervention: Aeroplane travel
Number of subjects: 77
Study: 24251881

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 24
Study: 21987535

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg/d for 7 days (aliskiren group, n = 10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (n = 6, no aliskiren)
Number of subjects: 16
Study: 20539300

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 19

Group type: COMPARATOR
Intervention: Non-DM Control
Number of subjects: 19
Study: 17136399

Group type: EXPERIMENTAL
Intervention: Lofexidine-naltrexone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo-naltrexone
Number of subjects: 18
Study: 16293536

Group type: EXPERIMENTAL
Intervention: Single concentration methacholine inhalation provocation test (SCIPT) with doses of 0.03-1.8 mg (maximal cumulated dose 3.6 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Standard dosimeter method (SDM) with doses of 0.002-1.8 mg (maximal cumulative dose 3.5 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of SCIPT and SDM
Number of subjects: 22
Study: 12081202

Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short course radiotherapy
Number of subjects: 0
Study: 9873842

Group type: EXPERIMENTAL
Intervention: Home treatment not available, less treatment in general
Number of subjects: 17

Group type: COMPARATOR
Intervention: Matched cohort from Malmö centre
Number of subjects: 17
Study: 8721461

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HC group, n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Uncoated circuits (UC group, n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuits (HC group)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Uncoated circuits (UC group)
Number of subjects: 18
Study: 1824527

Group type: EXPERIMENTAL
Intervention: 10 mg of diazepam
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg of nifedipine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg of propranolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 10 mg of nifedipine and 40 mg of propranolol
Number of subjects: 80
Study: 6339379

Group type: EXPERIMENTAL
Intervention: Oral killed polyvalent bacterial vaccine (3 courses over 2 months, each course containing 10^10 Haemophilus influenzae and 7 x 10^9 Staphylococcus aureus organisms)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral killed polyvalent bacterial vaccine
Number of subjects: 0
Study: 30565181

Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride oral solution (500 mg/5 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metformin hydrochloride tablets (500 mg)
Number of subjects: 24
Study: 28629886

Group type: EXPERIMENTAL
Intervention: Mindfulness and Self‐Compassion training program (2.5 hours/week for 8 weeks, 75% attendance, 45 minutes daily practice)
Number of subjects: 48
Study: 26590993

Group type: EXPERIMENTAL
Intervention: Rehabilitative intervention with a DVD showing exercises focused on facial muscles (PD-group-A)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Therapist-guided facial rehabilitation with a proprioceptive/recognition approach (PD-group-B)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (PD-Ctrl)
Number of subjects: 36
Study: 24393594

Group type: EXPERIMENTAL
Intervention: Biofeedback-based Nintendo Wii training
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Stillness test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nintendo Wii Agility test
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Time-of-day effect on COP variables
Number of subjects: 58
Study: 22494145

Group type: EXPERIMENTAL
Intervention: Family-centered intervention
Number of subjects: 713

Group type: EXPERIMENTAL
Intervention: Proactive parenting (dimension of positive behavior support)
Number of subjects: 713
Study: 18977579

Group type: COMPARATOR
Intervention: Oxytocin 5IU bolus and placebo infusion
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Oxytocin 5IU bolus and oxytocin 30IU infusion
Number of subjects: 110
Study: 18021388

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both SP and AQ
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Anti-GLURP-IgG antibodies
Number of subjects: 100

Group type: COMPARATOR
Intervention: Other malaria antigens
Number of subjects: 100
Study: 14727025

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 11993625

Group type: EXPERIMENTAL
Intervention: Regular carbohydrate‐electrolyte beverage (6.8% CHO, 18.7 mmol/L Na, 3.0 mmol/L K, 1,130 kJ/L)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low kilojoule electrolyte beverage (1% CHO, 18.7 mmol/L Na, 3.0 mmol/L K, 170 kJ/L)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Water
Number of subjects: 24
Study: 9818609

Group type: EXPERIMENTAL
Intervention: B/Y visual field
Number of subjects: 61

Group type: COMPARATOR
Intervention: W/W visual field
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: B/Y perimetry
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: RNFL assessment
Number of subjects: 61
Study: 7663799

Group type: EXPERIMENTAL
Intervention: CP-99,994 (250 micrograms/2 hours)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 1679668

Group type: EXPERIMENTAL
Intervention: Roxatidine 150 mg nocte
Number of subjects: 232

Group type: COMPARATOR
Intervention: Ranitidine 300 mg nocte
Number of subjects: 232
Study: 6352883

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Intensive conventional therapy (three or four daily injections of insulin)
Number of subjects: 19
Study: 31877773

Group type: EXPERIMENTAL
Intervention: High leptin/ghrelin ratio
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low leptin/ghrelin ratio
Number of subjects: 72

Group type: COMPARATOR
Intervention: Permissive underfeeding
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Leptin/ghrelin ratio
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Age and body mass index
Number of subjects: 72
Study: 29572761

Group type: EXPERIMENTAL
Intervention: Weekly administration of paclitaxel and carboplatin (W‐TC)
Number of subjects: 38

Group type: COMPARATOR
Intervention: 3 weeks of paclitaxel and carboplatin (TW‐TC)
Number of subjects: 38
Study: 27456885

Group type: EXPERIMENTAL
Intervention: PLISSIT model based sexual counseling (4 weekly sessions, 90-120 min each)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 88
Study: 24151926

Group type: COMPARATOR
Intervention: Incremental group (control) with composite resin (Tetric Ceram)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sandwich technique using resin modified glass ionomer (Fuji II LC)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sandwich technique using compomer (Compoglass F)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sandwich technique using flowable composite resin (Tetric Flow)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sandwich technique using self‐cure composite resin (Degufill SC)
Number of subjects: 50
Study: 21878455

Group type: EXPERIMENTAL
Intervention: BG-12 240 mg three times daily
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 19129277

Group type: EXPERIMENTAL
Intervention: Confrontational counselling by a nurse with nortriptyline for smoking cessation
Number of subjects: 296

Group type: COMPARATOR
Intervention: Regular counselling by a nurse with nortriptyline (control group 1)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Care as usual for smoking cessation by the general practitioner (control group 2)
Number of subjects: 296
Study: 17684153

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 28
Study: 15861940

Group type: EXPERIMENTAL
Intervention: Limited excision of the fistulous tract, wounds left opened for secondary intention healing.
Number of subjects: 83

Group type: COMPARATOR
Intervention: Closed wound group (wide resection of skin and subcutaneous tissue, followed by primary closure).
Number of subjects: 83

Group type: COMPARATOR
Intervention: Wide excision group (wide resection of skin and subcutaneous tissue, wounds left opened for secondary intention healing).
Number of subjects: 83
Study: 12470294

Group type: EXPERIMENTAL
Intervention: Intraglossal atropine
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Intravenous anticholinergic
Number of subjects: 804

Group type: EXPERIMENTAL
Intervention: Oral and intradeltoid anticholinergics
Number of subjects: 804

Group type: COMPARATOR
Intervention: Control group (no anticholinergic)
Number of subjects: 804
Study: 9583064

Group type: EXPERIMENTAL
Intervention: Attractive female therapist
Number of subjects: 241

Group type: COMPARATOR
Intervention: Less attractive female therapist
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Benign (communication) problem
Number of subjects: 241

Group type: COMPARATOR
Intervention: Potentially embarrassing (sexual) problem
Number of subjects: 241
Study: 8620668

Group type: EXPERIMENTAL
Intervention: Zileuton 600mg every 6 hours (q6h regimen)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Zileuton 600mg every 8 hours (q8h regimen)
Number of subjects: 12
Study: 2586434

Group type: EXPERIMENTAL
Intervention: Immunochemotherapy (IM-C) group
Number of subjects: 305

Group type: COMPARATOR
Intervention: Chemotherapy (control) group
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: OK-432 therapy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Regional infusion of LAK cells
Number of subjects: 305
Study: 1084659

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31282954

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: 224 mg of edonerpic maleate
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: 448 mg of edonerpic maleate
Number of subjects: 484
Study: 28129772

Group type: EXPERIMENTAL
Intervention: Iron polymaltose (IPM) 6 mg elemental iron/kg/day for 8 weeks
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: Iron polymaltose (IPM) in iron-replete children (serum ferritin ≥30 µg/l)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Placebo in iron-replete children (serum ferritin ≥30 µg/l)
Number of subjects: 591
Study: 25399822

Group type: EXPERIMENTAL
Intervention: Hydroxyurea therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal TCD measurements (Control group)
Number of subjects: 40
Study: 23451258

Group type: EXPERIMENTAL
Intervention: Motor Training (MT) alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation (iTBS) alone
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Motor Training (MT) + Intermittent Theta Burst Stimulation (iTBS)
Number of subjects: 82
Study: 21730007

Group type: EXPERIMENTAL
Intervention: Isolated systolic hypertension (ISH)
Number of subjects: 39260

Group type: EXPERIMENTAL
Intervention: Combined systolic-diastolic hypertension (SDH)
Number of subjects: 39260

Group type: EXPERIMENTAL
Intervention: Reported systolic blood pressure (SBP)
Number of subjects: 39260

Group type: EXPERIMENTAL
Intervention: Reported diastolic blood pressure (DBP)
Number of subjects: 39260

Group type: COMPARATOR
Intervention: Women without reported hypertension
Number of subjects: 39260
Study: 19191893

Group type: EXPERIMENTAL
Intervention: PACl14 (14 days)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PAM14 (14 days)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PACl10 (10 days)
Number of subjects: 592

Group type: COMPARATOR
Intervention: PAM10 (10 days)
Number of subjects: 592

Group type: COMPARATOR
Intervention: PACl7 (7 days)
Number of subjects: 592

Group type: COMPARATOR
Intervention: PAM7 (7 days)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PACl (clarithromycin)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: PAM (metronidazole)
Number of subjects: 592
Study: 16510864

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC) exercise
Number of subjects: 311

Group type: COMPARATOR
Intervention: Wellness education (WE)
Number of subjects: 311
Study: 14640239

Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 200 ng/ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous iron dextran (IVFe) infusion to achieve target serum ferritin concentrations of 400 ng/ml
Number of subjects: 0
Study: 10850936

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln mixture (3 g HMB, 14 g L-glutamine, and 14 g L-arginine given in two divided doses daily for 8 weeks)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: HMB/Arg/Gln mixture
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 9062567

Group type: EXPERIMENTAL
Intervention: Casting combined with stretching
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 9
Study: 8450520

Group type: EXPERIMENTAL
Intervention: Elemental calcium (2 g) for 12 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 20
Study: 3532297

Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg at night)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg at night)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg at night)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Antacids (as needed for symptomatic relief)
Number of subjects: 205
Study: 30368033

Group type: EXPERIMENTAL
Intervention: Food-based micronutrient supplement with loyalty cards
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food-based micronutrient supplement with price discounts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Retail distribution of micronutrient supplements
Number of subjects: 0
Study: 27393520

Group type: EXPERIMENTAL
Intervention: 0.45 mg oral conjugated equine estrogens (CEE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Transdermal E2 (50 μg/d) with micronized P (200 mg daily)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All groups (including CEE, E2, and placebo)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Race/Ethnicity
Number of subjects: 100
Study: 25027615

Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide (DM) syrup, age-weight dosing schedule (DM range 7.5-24.75 mg for Groups A and B; 30 mg for Group C)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Dextromethorphan hydrobromide (DM) syrup
Number of subjects: 38
Study: 22419715

Group type: EXPERIMENTAL
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during hyperinsulinemic clamp (80 mU/m2 · min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during saline infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: GnRH agonist stimulation (buserelin 100 μg, s.c.) during both hyperinsulinemia and saline infusion
Number of subjects: 9
Study: 20166410

Group type: EXPERIMENTAL
Intervention: High value composite (GHV)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Medium value composite (GMV)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Low value composite (GLV)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 65
Study: 18616643

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg tablet twice daily for 24 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg tablet
Number of subjects: 50
Study: 16088104

Group type: EXPERIMENTAL
Intervention: Dialysate bicarbonate at 32 mmol/l (modality A)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dialysate bicarbonate at 26 mmol/l (modality B)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dialysate calcium at 1.50 mmol/l (modality C)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of modality A with ACE inhibitors or angiotensin II blockers
Number of subjects: 27

Group type: COMPARATOR
Intervention: Comparison between modalities A and B
Number of subjects: 27
Study: 12205647

Group type: EXPERIMENTAL
Intervention: Midodrine (5mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10613449

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with idarubicin (IDA) 12 mg/m2/day i.v. bolus (days 1 to 3)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) 200 mg/m2/day continuous infusion (days 3 to 7) with mitoxantrone (MIT) 12 mg/m2/day i.v. bolus (days 1 to 3)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) with idarubicin (IDA)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Carboplatin (CBP) with mitoxantrone (MIT)
Number of subjects: 53
Study: 8526957

Group type: EXPERIMENTAL
Intervention: 0.15 mg/kg mivacurium (2 x ED95)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.015 mg/kg mivacurium (20% of ED95) followed by 0.07 mg/kg mivacurium (ED95)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.46 mg/kg atracurium (2 x ED95)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.046 mg/kg atracurium (20% of ED95) followed by 0.23 mg/kg atracurium (ED95)
Number of subjects: 48
Study: 1835110

Group type: EXPERIMENTAL
Intervention: Nebulised ipratropium 0.5 mg and fenoterol 1.25 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study: 7124560

Group type: EXPERIMENTAL
Intervention: Students attached to geriatric firms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Students attached to general medical firms
Number of subjects: 0
Study: 29699472

Group type: EXPERIMENTAL
Intervention: Emotional intelligence training program (3 weeks)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Emotional intelligence training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo control training program
Number of subjects: 59
Study: 28952166

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 64

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Both treatments (Haloperidol and Olanzapine)
Number of subjects: 64
Study: 25872457

Group type: EXPERIMENTAL
Intervention: DEM-DISC (accessed for 12 months)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: DEM-DISC (frequent access)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (no access to DEM-DISC)
Number of subjects: 73